# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $328 to $...
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key s...